Cargando…

Olanzapine long-acting injection: a review of first experiences of post-injection delirium/sedation syndrome in routine clinical practice

BACKGROUND: Olanzapine long-acting injection (LAI) for the treatment of schizophrenia was associated with a cluster of symptoms termed post-injection delirium/sedation syndrome (PDSS) in a small percentage (~2%) of patients during clinical trials. The objective of this analysis was to evaluate the r...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bushe, Chris J, Falk, Deborah, Anand, Ernie, Casillas, Marta, Perrin, Elena, Chhabra-Khanna, Rashna, Detke, Holland C
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4389990/ https://www.ncbi.nlm.nih.gov/pubmed/25886006 http://dx.doi.org/10.1186/s12888-015-0450-9

Ejemplares similares

Postinjection delirium/sedation syndrome in patients with schizophrenia receiving olanzapine long-acting injection: results from a large observational study
por: Meyers, Kristin J., et al.
Publicado: (2017)

Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, I: analysis of cases
por: Detke, Holland C, et al.
Publicado: (2010)

Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, II: investigations of mechanism
por: McDonnell, David P, et al.
Publicado: (2010)

Clinical outcomes with olanzapine long-acting injection: impact of the 3-hour observation period on patient satisfaction and well-being
por: Anand, Ernie, et al.
Publicado: (2016)

Switching to olanzapine long-acting injection from either oral olanzapine or any other antipsychotic: comparative post hoc analyses
por: Ciudad, Antonio, et al.
Publicado: (2013)

Pharmacokinetics of olanzapine long-acting injection: the clinical perspective
por: Heres, Stephan, et al.
Publicado: (2014)

Baseline characteristics and hospitalizations in patients with schizophrenia receiving olanzapine long-acting injection: an interim analysis from a non-interventional, prospective observational safety study
por: Jones, Meghan E., et al.
Publicado: (2015)

Postinjection Delirium/Sedation Syndrome with Olanzapine Depot Injection
por: Sarangula, Sadhvi Mythili, et al.
Publicado: (2016)

Case series profile of olanzapine post‐injection delirium/sedation syndrome
por: Seebaluck, Jason, et al.
Publicado: (2022)

A pooled analysis of injection site-related adverse events in patients with schizophrenia treated with olanzapine long-acting injection
por: Atkins, Susan, et al.
Publicado: (2014)

Within‐drug benefit‐risk evaluation of olanzapine long‐acting injection at one and two years of treatment
por: Detke, Holland C., et al.
Publicado: (2014)

Long-term functional improvements in the 2-year treatment of schizophrenia outpatients with olanzapine long-acting injection
por: Ascher-Svanum, Haya, et al.
Publicado: (2014)

Efficacy of olanzapine long-acting injection in patients with acutely exacerbated schizophrenia: an insight from effect size comparison with historical oral data
por: Detke, Holland C, et al.
Publicado: (2012)

Long-term safety and efficacy of olanzapine long-acting injection in patients with schizophrenia or schizoaffective disorder: a 6-year, multinational, single-arm, open-label study
por: McDonnell, David P., et al.
Publicado: (2014)

Predictors of psychiatric hospitalization during 6 months of maintenance treatment with olanzapine long-acting injection: post hoc analysis of a randomized, double-blind study
por: Ascher-Svanum, Haya, et al.
Publicado: (2013)

Postinjection delirium/sedation syndrome with long-acting olanzapine pamoate in a middle-aged female
por: Upadhyay, Apoorva, et al.
Publicado: (2017)

Early response predicts subsequent response to olanzapine long-acting injection in a randomized, double-blind clinical trial of treatment for schizophrenia
por: Ascher-Svanum, Haya, et al.
Publicado: (2011)

Long-acting injectable antipsychotics: focus on olanzapine pamoate
por: Lindenmayer, JP
Publicado: (2010)

Patient and Health Care Provider Perspectives on Long Acting Injectable Antipsychotics in Schizophrenia and the Introduction of Olanzapine Long-Acting Injection
por: Wehring, Heidi J., et al.
Publicado: (2011)

A 6-year open-label study of the efficacy and safety of olanzapine long-acting injection in patients with schizophrenia: a post hoc analysis based on the European label recommendation
por: Anand, Ernie, et al.
Publicado: (2015)

Profile of olanzapine long-acting injection for the maintenance treatment of adult patients with schizophrenia
por: Di Lorenzo, Rosaria, et al.
Publicado: (2010)

Patient perspectives in the development and use of long-acting antipsychotics in schizophrenia: focus on olanzapine long-acting injection
por: Citrome, Leslie
Publicado: (2009)

Are the Long-Acting Intramuscular Formulations of Risperidone or Paliperidone Palmitate Associated with Post-Injection Delirium/Sedation Syndrome? An Assessment of Safety Databases
por: Alphs, Larry, et al.
Publicado: (2011)

Evaluating adult forensic staff knowledge of olanzapine long-acting injection post injection syndrome: a service improvement project
por: Clark, Annalie, et al.
Publicado: (2021)

Intramuscular Olanzapine – a UK case series of early cases
por: Bushe, Chris J, et al.
Publicado: (2007)

Quality of life in children and adolescents with bipolar I depression treated with olanzapine/fluoxetine combination
por: Walker, Daniel J., et al.
Publicado: (2017)

A study on blood pressure changes following Olanzapine Long Acting Injection (LAI) in schizophrenia
por: Gakkhar, Shivam, et al.
Publicado: (2022)

Post-Injection Delirium/Sedation Syndrome: A Case Report and 2-Year Follow-Up
por: Podgorná, Gabriela, et al.
Publicado: (2022)

Treatment-completion rates with olanzapine long-acting injection versus risperidone long-acting injection in a 12-month, open-label treatment of schizophrenia: indirect, exploratory comparisons
por: Ascher-Svanum, Haya, et al.
Publicado: (2012)

Comparison of efficacy of haloperidol and olanzapine in the treatment of delirium
por: Jain, Rajan, et al.
Publicado: (2017)

Acute Metabolic Effects of Olanzapine Depend on Dose and Injection Site
por: Klingerman, Candice M., et al.
Publicado: (2015)

Schizophrenia symptoms and functioning in patients receiving long-term treatment with olanzapine long-acting injection formulation: a pooled analysis
por: Peuskens, Joseph, et al.
Publicado: (2012)

Olanzapine long-acting injection, discontinuation rates and reasons for discontinuation: 10 years’ experience at a UK high-secure hospital
por: Attard, Azizah, et al.
Publicado: (2022)

Additional sedative drugs to light sedation with dexmedetomidine is risk for delirium
por: Sakuraya, M, et al.
Publicado: (2015)

Levomepromazine: Delirium and sedation: case report
Publicado: (2021)

Delirium Associated with Olanzapine Therapy in an Elderly Male with Bipolar Affective Disorder
por: Sharma, Ravi C., et al.
Publicado: (2010)

Letter to editor regarding “comparison of efficacy of haloperidol and olanzapine in the treatment of delirium”
por: Kumar, Pawan, et al.
Publicado: (2019)

Olanzapine for the treatment of ICU delirium: a systematic review and meta-analysis
por: Liu, Si Bo, et al.
Publicado: (2023)

Dose-associated changes in safety and efficacy parameters observed in a 24-week maintenance trial of olanzapine long-acting injection in patients with schizophrenia
por: Hill, Angela L, et al.
Publicado: (2011)

Switch from Olanzapine Long-Acting Injectable to its Oral Equivalent during COVID-19 Pandemic: a Real World Observational Study
por: Miron, Ana-Aliana, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_jjf6shk6sbclqd18t4ntt52q44